NCT03876769 2026-03-13
CASSIOPEIA
Novartis
Phase 2 Active not recruiting
Clinical Trials
28 trialsNCT06785818 2026-02-23
Long-term Follow up Local Registry Study of Kymriah in South Korea
Novartis
Recruiting
NCT05888493 2026-02-20
LEDA
Novartis
Phase 3 Active not recruiting
NCT04094311 2026-02-17
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT06408194 2026-02-10
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Stanford University
Phase 1 Recruiting
NCT05460533 2026-02-04
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05633615 2026-02-02
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network
Phase 2 Recruiting
NCT03642626 2026-01-23
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2 Active not recruiting
NCT04855253 2026-01-15
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
Masonic Cancer Center, University of Minnesota
Phase 1/2 Suspended
NCT03601442 2025-12-05
CTL019 Out of Specification MAP for ALL or DLBCL Patients
Novartis
Available
NCT05075603 2025-10-23
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
NeoImmuneTech
Phase 1 Completed
NCT03568461 2025-10-07
ELARA
Novartis
Phase 2 Completed
NCT04419909 2025-07-02
Retreatment With CTL019/CTL119
University of Pennsylvania
Phase 1 Not yet recruiting
NCT05541341 2025-06-06
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Novartis
Recruiting
NCT04890236 2025-01-20
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Emory University
Phase EARLY_PHASE1 Completed
NCT04234061 2024-11-07
TARMAC
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting
NCT03610724 2024-06-20
BIANCA
Novartis
Phase 2 Completed
NCT02445248 2024-04-18
JULIET
Novartis
Phase 2 Completed
NCT02435849 2024-02-13
ELIANA
Novartis
Phase 2 Completed
NCT04161118 2023-05-06
TIGER-CTL019
University of Cologne
Phase 2 Terminated
NCT03876028 2023-01-31
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
Novartis
Phase 1 Terminated
NCT05541328 2022-09-15
Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel
Novartis
Completed
NCT03630159 2022-08-15
PORTIA
Novartis
Phase 1 Completed
NCT05349201 2022-07-01
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)
Novartis
Completed
NCT02529813 2022-06-30
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04456023 2022-03-02
Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
Novartis
Phase 2 Withdrawn
NCT03123939 2021-07-21
Phase III B in Acute Lymphoblastic Leukemia
Novartis
Phase 3 Completed
NCT02228096 2020-11-23
ENSIGN
Novartis
Phase 2 Completed